Annovis Bio Inc (ANVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annovis Bio Inc (ANVS) has a cash flow conversion efficiency ratio of -0.530x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.93 Million) by net assets ($16.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Annovis Bio Inc net asset quality index to measure how much of total assets are equity-financed.
Annovis Bio Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Annovis Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Annovis Bio Inc (ANVS) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annovis Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annovis Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DCM Corp
KO:024090
|
0.019x |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
-0.037x |
|
PT Ingria Pratama Capitalindo Tbk
JK:GRIA
|
0.071x |
|
Yojee Ltd
AU:YOJ
|
-0.167x |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
-0.056x |
|
Menderes Tekstil Sanayi ve Ticaret AS
IS:MNDRS
|
0.046x |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
0.029x |
|
Chien Shing Stainless Steel Co Ltd
TW:2025
|
0.014x |
Annual Cash Flow Conversion Efficiency for Annovis Bio Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Annovis Bio Inc (ANVS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.85 Million | $-25.62 Billion | -1520.344x | +35.37% |
| 2024-12-31 | $9.31 Million | $-21.89 Billion | -2352.325x | -45718.55% |
| 2023-12-31 | $-7.75 Million | $-39.97 Million | 5.157x | +943.59% |
| 2022-12-31 | $28.32 Million | $-17.31 Million | -0.611x | -197.82% |
| 2021-12-31 | $44.49 Million | $-9.13 Million | -0.205x | +61.02% |
| 2020-12-31 | $7.54 Million | $-3.97 Million | -0.527x | -1047.67% |
| 2019-12-31 | $-8.58 Million | $-476.54K | 0.056x | -24.46% |
| 2018-12-31 | $-7.59 Million | $-558.61K | 0.074x | -4.67% |
| 2017-12-31 | $-6.97 Million | $-537.48K | 0.077x | +114.53% |
| 2012-12-31 | $2.66 Million | $-1.41 Million | -0.531x | -145.69% |
| 2011-12-31 | $13.93 Million | $-3.01 Million | -0.216x | -100.99% |
| 2010-12-31 | $16.49 Million | $-1.77 Million | -0.108x | +59.22% |
| 2009-12-31 | $1.48 Million | $-389.23K | -0.264x | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more